Liquidia (LQDA) Share-based Compensation (2020 - 2026)
Liquidia (LQDA) recorded quarterly Share-based Compensation of $9.2 million in Q1 2026, up 27.91% quarter-over-quarter from $7.2 million in Q4 2025, and up 23.92% on a YoY basis from $7.4 million in Q1 2025.
Liquidia (LQDA) Share-based Compensation (2020 - 2026) Analysis & Trends
Liquidia's Share-based Compensation history runs 7 years deep, the most recent figure standing at $9.2 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 23.92% year-over-year to $9.2 million; the TTM figure through Mar 2026 stood at $31.3 million (up 43.88% YoY), while the FY2025 annual figure was $29.5 million, up 56.72% from the prior year.
- Share-based Compensation was $9.2 million for Q1 2026 at Liquidia, up from $7.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $9.2 million in Q1 2026 to a low of $4185.0 in Q1 2022.
- Historically, Share-based Compensation has averaged $4.3 million across 5 years, with a median of $4.4 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 73.04% in 2022, then surged 60879.69% in 2023.
- A 5-year view of Share-based Compensation shows it stood at $1.8 million in 2022, then jumped by 40.32% to $2.6 million in 2023, then jumped by 97.14% to $5.0 million in 2024, then jumped by 43.29% to $7.2 million in 2025, then gained by 27.91% to $9.2 million in 2026.
- The last three Share-based Compensation figures came in at $9.2 million (Q1 2026), $7.2 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 16.04 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 36.86 Mn |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | 9.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.22 Mn |
| Mar 31, 2026 | 9.22 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Dec 31, 2025 | 7.21 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Sep 30, 2025 | 7.90 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Mar 31, 2025 | 7.44 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Jun 30, 2024 | 4.37 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 2.55 Mn |
| Dec 31, 2023 | 2.55 Mn |